pharmaphorum August 5, 2024
Phil Taylor

An FDA advisory committee has recommended approval of Zevra Therapeutics’ arimoclomol for the ultra-rare disorder Niemann-Pick disease, three years after the regulator rejected the drug.

The Genetic Metabolic Diseases Advisory Committee (GeMDAC) voted 11 to five that the data support the approval of the drug for Niemann-Pick disease type C (NPC), a progressive genetic disorder that leads to the accumulation of fatty substances in tissues and can cause a range of symptoms, including liver and lung disease and neurological impairment.

In June 2021, when arimoclomol was owned by Danish biotech Orphazyme, the FDA issued a complete response letter for the drug and asked for an additional clinical trial, setting the programme back.

After the EMA’s human medicines committee also said...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma, Pharma / Biotech
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency
Opinion: To fight for those with rare diseases, Trump must reform and modernize the FDA thoughtfully
5 Rare Diseases That Now Have Their First FDA-Approved Treatments

Share This Article